| Access Dental Care Pc | |
|
119 W South St Groton NY 13073-1234 | |
| (607) 898-5006 | |
| (607) 898-9000 |
| Full Name | Access Dental Care Pc |
|---|---|
| Speciality | Dentist |
| Location | 119 W South St, Groton, New York |
| Authorized Official Name and Position | Neelam A Ali (OFFICE MANAGER) |
| Authorized Official Contact | 6078985006 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Access Dental Care Pc 119 W South St Groton NY 13073-1234 Ph: (607) 898-5006 | Access Dental Care Pc 119 W South St Groton NY 13073-1234 Ph: (607) 898-5006 |
| NPI Number | 1821344409 |
|---|---|
| Provider Enumeration Date | 08/01/2012 |
| Last Update Date | 07/21/2022 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821344409 | NPI | - | NPPES |
| 02330261 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | (New York) | Primary |
News Archive
A Viewpoint in this week's issue of THE LANCET addresses the state of primary-care research worldwide. Primary care includes the medical services provided by general practitioners (family physicians) and internists, with the aims of providing patients with a broad range of health care over a period of time and coordinating the care the patient receives.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.
WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year.
Only 2 of 15 Medicare programs designed to improve care and costs for patients with chronic illnesses resulted in reduced hospital admissions, and none of the programs generated net savings, according to a study in the February 11 issue of JAMA.
Center for iPS Cell Research Application of Kyoto University and Takeda Pharmaceutical Company Limited announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy.
› Verified 1 days ago